Longeveron logo
Longeveron
LGVN | NASDAQ
Chart Builder DCF Calculator
$2.14
-$0.35 (-14.06%)
At close: Nov 16, 2026, 4:00 PM ET
$2.14
$0.00 (0.00%)
After-hours: Nov 16, 2026, 7:30 PM ET

Longeveron Company Profile

Company profile explained

Company Profile

Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditions and various critical, life-threatening illnesses. The company's primary investigational product is LOMECEL-B, a sophisticated cellular therapy. This product is created from medicinal signaling cells that are cultivated and expanded after being harvested from the bone marrow of healthy young adult donors. Longeveron is actively conducting Phase 1 and Phase 2 clinical trials to evaluate LOMECEL-B's potential across a diverse range of indications. These include age-related frailty, Alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome (ARDS), and hypoplastic left heart syndrome (HLHS). Established in 2014, Longeveron Inc. operates from its headquarters in Miami, Florida.

Key Executives

Name Position
Stephen H. Willard Chief Executive Officer & Director
Devin Blass Chief Technology Officer & Senior Vice President of Chemistry, Manufacturing, and Controls
Brian Rash Vice President of Research & Discovery
Joshua Michael Hare FACC Co-Founder, Chief Science Officer & Executive Chairman
Lisa McClain-Moss Vice President of Manufacturing
Marie Washburn Vice President & Corporate Controller
Nataliya Agafonova Chief Medical Officer
Nirav Suresh Jhaveri CFO and Principal Financial & Accounting Officer
Paul T. Lehr General Counsel & Secretary

Latest SEC Filings

Date Type Title
Oct 26, 2026 8-K Current Report
Oct 14, 2026 8-K Current Report
Oct 05, 2026 4 Filing
Oct 05, 2026 4 Filing
Oct 05, 2026 4 Filing
Oct 05, 2026 4 Filing
Oct 05, 2026 4 Filing
Sep 23, 2026 8-K Current Report
Sep 14, 2026 8-K Current Report
Sep 10, 2026 SC 13G Statement of acquisition of beneficial ownership b...
View All SEC Filings ➞
Longeveron
Longeveron logo
Country United States
IPO Date Feb 12, 2021
Industry Biotechnology
Sector Healthcare
Employees 38
CEO Stephen H. Willard

Contact Details

Life Science & Technology Park Miami, Florida 33136 United States

Stock Details

Ticker Symbol LGVN
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001721484
CUSIP Number 54303L302
ISIN Number US54303L3024
SIC Code 2834

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.